In the Netherlands, SGLT2 inhibitors are the preferred choice of therapy in T2D patients with a very high risk for cardiovascular events due to its shown benefits in preventing cardiovascular disease (CVD) events and progression of CKD [14]. The gene discussed is SLC5A2; the disease is chronic kidney disease.